(BN) Danone - Ratings and Ratios
Yogurt, Plant Milk, Baby Formula, Water, Medical Nutrition
Dividends
| Dividend Yield | 2.82% |
| Yield on Cost 5y | 4.90% |
| Yield CAGR 5y | 0.00% |
| Payout Consistency | 95.1% |
| Payout Ratio | 75.4% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 14.3% |
| Value at Risk 5%th | 21.8% |
| Relative Tail Risk | -7.42% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.91 |
| Alpha | 19.74 |
| CAGR/Max DD | 1.45 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.396 |
| Beta | -0.167 |
| Beta Downside | -0.122 |
| Drawdowns 3y | |
|---|---|
| Max DD | 13.40% |
| Mean DD | 3.28% |
| Median DD | 2.39% |
Description: BN Danone December 04, 2025
Danone S.A. (ticker BN) is a global food and beverage group headquartered in Paris, France, operating across Europe, North America, Asia, Africa, the Middle East, and the CIS. The company is organized into three business segments: Essential Dairy & Plant-Based, Specialized Nutrition, and Waters.
Its product portfolio spans yogurts, dairy and plant-based drinks, coffee-based beverages, ice-cream, cheese, and a range of specialized nutrition solutions-including infant formulas, medical-purpose foods, tube-feeding products, and oral nutritional supplements. The Waters segment supplies natural mineral waters, fruit-infused waters, juices, and vitamin-enhanced drinks.
Key brands include Actimel, Activia, Alpro, Aptamil, Danone, Oikos, Silk, So Delicious, Evian, Volvic, Bonafont, and many regional names such as SToK and Zywiec Zdroj. Distribution channels cover retail chains, convenience stores, food-service outlets, hospitals and pharmacies, as well as growing e-commerce platforms.
From a financial-performance perspective, Danone reported €26.9 billion in net sales for FY 2023, with an adjusted EBITDA margin of roughly 12 %. The Essential Dairy & Plant-Based segment delivered a 10 % year-over-year revenue increase, driven largely by plant-based product adoption and premiumization trends.
Sector-level drivers that materially affect Danone include commodity price volatility (milk, sugar, and aluminum), inflationary pressure on consumer spending, and regulatory scrutiny of infant-formula marketing. Additionally, the global shift toward healthier, sustainable food choices underpins growth opportunities in plant-based and premium water categories.
For a deeper quantitative assessment, you might explore Danone’s valuation metrics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (2.85b TTM) > 0 and > 6% of Revenue (6% = 3.27b TTM) |
| FCFTA 0.13 (>2.0%) and ΔFCFTA 5.69pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -1.32% (prev -3.67%; Δ 2.36pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.17 (>3.0%) and CFO 7.37b > Net Income 2.85b (YES >=105%, WARN >=100%) |
| Net Debt (12.92b) to EBITDA (9.30b) ratio: 1.39 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.95 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (644.4m) change vs 12m ago 0.45% (target <= -2.0% for YES) |
| Gross Margin 49.46% (prev 46.67%; Δ 2.79pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 122.3% (prev 76.08%; Δ 46.26pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.41 (EBITDA TTM 9.30b / Interest Expense TTM 1.31b) >= 6 (WARN >= 3) |
Altman Z'' 2.70
| (A) -0.02 = (Total Current Assets 12.90b - Total Current Liabilities 13.62b) / Total Assets 43.76b |
| (B) 0.39 = Retained Earnings (Balance) 17.23b / Total Assets 43.76b |
| (C) 0.16 = EBIT TTM 7.08b / Avg Total Assets 44.60b |
| (D) 0.44 = Book Value of Equity 12.16b / Total Liabilities 27.84b |
| Total Rating: 2.70 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 78.14
| 1. Piotroski 5.50pt |
| 2. FCF Yield 9.26% |
| 3. FCF Margin 10.14% |
| 4. Debt/Equity 0.92 |
| 5. Debt/Ebitda 1.39 |
| 6. ROIC - WACC (= 14.53)% |
| 7. RoE 17.12% |
| 8. Rev. Trend 46.47% |
| 9. EPS Trend -3.74% |
What is the price of BN shares?
Over the past week, the price has changed by -1.06%, over one month by -1.19%, over three months by +1.47% and over the past year by +20.61%.
Is BN a buy, sell or hold?
What are the forecasts/targets for the BN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 78.8 | 3.4% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 90.7 | 19.1% |
BN Fundamental Data Overview December 06, 2025
Market Cap EUR = 51.26b (51.26b EUR * 1.0 EUR.EUR)
P/E Trailing = 27.9298
P/E Forward = 19.4932
P/S = 1.7933
P/B = 3.1107
P/EG = 2.7078
Beta = 0.246
Revenue TTM = 54.56b EUR
EBIT TTM = 7.08b EUR
EBITDA TTM = 9.30b EUR
Long Term Debt = 9.88b EUR (from longTermDebt, last quarter)
Short Term Debt = 3.96b EUR (from shortTermDebt, last quarter)
Debt = 14.54b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.92b EUR (from netDebt column, last quarter)
Enterprise Value = 59.78b EUR (51.26b + Debt 14.54b - CCE 6.01b)
Interest Coverage Ratio = 5.41 (Ebit TTM 7.08b / Interest Expense TTM 1.31b)
FCF Yield = 9.26% (FCF TTM 5.54b / Enterprise Value 59.78b)
FCF Margin = 10.14% (FCF TTM 5.54b / Revenue TTM 54.56b)
Net Margin = 5.22% (Net Income TTM 2.85b / Revenue TTM 54.56b)
Gross Margin = 49.46% ((Revenue TTM 54.56b - Cost of Revenue TTM 27.58b) / Revenue TTM)
Gross Margin QoQ = 50.90% (prev 50.04%)
Tobins Q-Ratio = 1.37 (Enterprise Value 59.78b / Total Assets 43.76b)
Interest Expense / Debt = 2.49% (Interest Expense 362.0m / Debt 14.54b)
Taxrate = 25.78% (373.0m / 1.45b)
NOPAT = 5.25b (EBIT 7.08b * (1 - 25.78%))
Current Ratio = 0.95 (Total Current Assets 12.90b / Total Current Liabilities 13.62b)
Debt / Equity = 0.92 (Debt 14.54b / totalStockholderEquity, last quarter 15.86b)
Debt / EBITDA = 1.39 (Net Debt 12.92b / EBITDA 9.30b)
Debt / FCF = 2.33 (Net Debt 12.92b / FCF TTM 5.54b)
Total Stockholder Equity = 16.64b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.51% (Net Income 2.85b / Total Assets 43.76b)
RoE = 17.12% (Net Income TTM 2.85b / Total Stockholder Equity 16.64b)
RoCE = 26.69% (EBIT 7.08b / Capital Employed (Equity 16.64b + L.T.Debt 9.88b))
RoIC = 19.14% (NOPAT 5.25b / Invested Capital 27.45b)
WACC = 4.62% (E(51.26b)/V(65.80b) * Re(5.40%) + D(14.54b)/V(65.80b) * Rd(2.49%) * (1-Tc(0.26)))
Discount Rate = 5.40% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 33.33 | Cagr: 0.20%
[DCF Debug] Terminal Value 77.44% ; FCFE base≈4.59b ; Y1≈4.34b ; Y5≈4.11b
Fair Price DCF = 114.2 (DCF Value 73.54b / Shares Outstanding 644.0m; 5y FCF grow -7.05% → 3.0% )
EPS Correlation: -3.74 | EPS CAGR: -0.65% | SUE: -0.32 | # QB: 0
Revenue Correlation: 46.47 | Revenue CAGR: 6.32% | SUE: 0.67 | # QB: 0
EPS next Year (2026-12-31): EPS=4.07 | Chg30d=+0.036 | Revisions Net=+19 | Growth EPS=+6.8% | Growth Revenue=+3.0%